Medigene AG - Stock Quote MDGEF
Morningstar's Medigene AG Stock Analysis
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Medigene AG's Company Profile
Medigene AG is a Germany based biotechnology company. Along with its subsidiaries, the company is primarily engaged in developing immunotherapies to target various forms and stages of cancer with candidates in clinical and pre-clinical development. The group is focused on the development of personalized T cell-based therapies. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy, DC vaccines, and T-cell-specific monoclonal antibodies. The group operates in the United States, Europe, and Other countries, of which majority of the revenue is derived from operations in the United States.